CD8A and neoplasm: In sum, the potential benefits of FasL neutralization for cancer immunotherapy, particularly in the context of adoptive cell therapy, are fourfold: (i) preventing TIL apoptosis induced by FasL-expressing PMN-MDSC, (ii) improving CD8+ T-cell infiltration into the tumor by preventing apoptosis induced by endothelial cells, (iii) improving T-cell persistence at the tumor site by inhibiting the immune checkpoint relying on AICD, (iv) improving T-cell persistence and activity by preventing precocious differentiation of naive T cells induced by co-injected memory T cells.